Table 1 Clinicopathologic features of the patients (n = 229)
Characteristics | Overall | Training | Test | P value |
|---|---|---|---|---|
n = 229 (%) | n = 160 (%) | n = 69 (%) | ||
Age (years), Median [IQR] | 51 [45, 60] | 52.0 [44, 63] | 50.0 [45, 59] | 0.321 |
Tumor size (cm), Median [IQR] | 2.0 [1.5, 3.0] | 2.0 [1.7, 3.0] | 2.0 [1.5, 3.0] | 0.483 |
T stage (AJCC 8 th) |  |  |  | 0.134 |
 T1 | 117 (51.1) | 86 (53.8) | 31 (44.9) |  |
 T2 | 101 (44.1) | 69 (43.1) | 32 (46.4) |  |
 T3 | 11 (4.8) | 5 (3.1) | 6 (8.7) |  |
N stage (AJCC 8 th) |  |  |  | 0.368 |
 N0 | 71 (31.0) | 53 (33.1) | 18 (26.1) |  |
 N +  | 158 (69.0) | 107 (66.9) | 51 (73.9) |  |
M stage (AJCC 8 th) |  |  |  | 0.861 |
 M0 | 226 (98.7) | 158 (98.8) | 68 (98.6) |  |
 M1 | 3 (1.3) | 2 (1.2) | 1 (1.4) |  |
TNM stage (AJCC 8 th) |  |  |  | 0.677 |
 I | 45 (19.7) | 34 (21.2) | 11 (15.9) |  |
 II | 80 (34.9) | 57 (35.6) | 23 (33.3) |  |
 III | 101 (44.1) | 67 (41.9) | 34 (49.3) |  |
 IV | 3 (1.3) | 2 (1.2) | 1 (1.4) |  |
ER status | Â | Â | Â | 0.289 |
 Negative | 26 (11.4) | 21 (13.1) | 5 (7.2) |  |
 Positive | 203 (88.6) | 139 (86.9) | 64 (92.8) |  |
ER Intensity | Â | Â | Â | 0.200 |
 - | 26 (11.4) | 21 (13.1) | 5 (7.2) |  |
   +  | 14 (6.1) | 12 (7.5) | 2 (2.9) |  |
   + +  | 57 (24.9) | 41 (25.6) | 16 (23.2) |  |
   + + +  | 132 (57.6) | 86 (53.8) | 46 (66.7) |  |
PR status | Â | Â | Â | 0.511 |
 Negative | 30 (13.1) | 23 (14.4) | 7 (10.1) |  |
 Positive | 199 (86.9) | 137 (85.6) | 62 (89.9) |  |
PR Intensity | Â | Â | Â | 0.995 |
 - | 35 (15.3) | 25 (15.6) | 10 (14.5) |  |
   +  | 24 (10.5) | 17 (10.6) | 7 (10.1) |  |
   + +  | 62 (27.1) | 43 (26.9) | 19 (27.5) |  |
   + + +  | 108 (47.2) | 75 (46.9) | 33 (47.8) |  |
Her- 2 status | Â | Â | Â | 0.952 |
 Negative | 157 (68.6) | 109 (68.1) | 48 (69.6) |  |
 Positive | 72 (31.4) | 51 (31.9) | 21 (30.4) |  |
Ki- 67 (%), median [IQR] | 30 [20, 40] | 30 [20, 32] | 30 [20, 40] | 0.821 |
Subtype | Â | Â | Â | Â |
 Luminal A | 17 (7.4) | 16 (10.0) | 1 (1.4) | 0.054 |
 Luminal B | 194 (84.7) | 130 (81.2) | 64 (92.8) |  |
 Her- 2 overexpression | 13 (5.7) | 9 (5.6) | 4 (5.8) |  |
 TNBC | 5 (2.2) | 5 (3.1) | 0 (0.0) |  |
p53 (%), median [IQR] | 5.0 [1.0, 15] | 5.0 [1.0, 15] | 5.0 [2.0, 25] | 0.143 |
CK5/6 | Â | Â | Â | 0.583 |
 Negative | 218 (95.2) | 151 (94.4) | 67 (97.1) |  |
 Positive | 11 (4.8) | 9 (5.6) | 2 (2.9) |  |
LVI | Â | Â | Â | 0.449 |
 - | 26 (11.4) | 16 (10.0) | 10 (14.5) |  |
   +  | 203 (88.6) | 144 (90.0) | 59 (85.5) |  |
Histological grade | Â | Â | Â | 0.973 |
 I | 21 (9.2) | 15 (9.4) | 6 (8.7) |  |
 II | 160 (69.9) | 112 (70.0) | 48 (69.6) |  |
 III | 48 (21.0) | 33 (20.6) | 15 (21.7) |  |